SPRR2A and neoplasm: We then administered either rmIL-12, mIL-12hFc WT or mIL-12hFc NHQ i.t. to C57BL/6 WT mice (hFcRn Tg32 we deemed not suitable as mFcRn deficiency negatively impacts immune competence30,31) bearing well established orthotopic GL-261 luciferase-expressing tumors, on days 21 and 28 post-tumor inoculation (Fig. 3A).